Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has accepted...
Trinomab Biotech
Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai
China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...
Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA
China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...
Trinomab’s TNM002 Antitetanus Monoclonal Antibody Filing Accepted for Review in China
China’s Center for Drug Evaluation (CDE) has accepted Trinomab Biotech Co., Ltd.’s market approval filing...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...